share_log

Piper Sandler Reiterates Overweight on NovoCure, Raises Price Target to $28

Moomoo 24/7 ·  Apr 10 08:55

Piper Sandler analyst Jason Bednar reiterates NovoCure (NASDAQ:NVCR) with a Overweight and raises the price target from $25 to $28.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment